Parnassus Investments LLC Sells 105,328 Shares of Hologic, Inc. (NASDAQ:HOLX)

Parnassus Investments LLC lowered its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 9.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,063,421 shares of the medical equipment provider's stock after selling 105,328 shares during the quarter. Parnassus Investments LLC owned about 0.47% of Hologic worth $76,662,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. General Partner Inc. bought a new stake in Hologic during the 4th quarter valued at about $26,000. Venturi Wealth Management LLC lifted its position in shares of Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after buying an additional 261 shares in the last quarter. First Horizon Advisors Inc. boosted its position in shares of Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock worth $39,000 after purchasing an additional 134 shares during the period. EverSource Wealth Advisors LLC increased its stake in shares of Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 260 shares in the last quarter. Finally, Smartleaf Asset Management LLC raised its position in shares of Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after purchasing an additional 159 shares during the period. Hedge funds and other institutional investors own 94.73% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

HOLX has been the subject of several recent analyst reports. Raymond James reaffirmed an "outperform" rating and set a $90.00 price objective (down from $95.00) on shares of Hologic in a report on Thursday, February 6th. BNP Paribas upgraded shares of Hologic to a "strong-buy" rating in a report on Tuesday, December 10th. Leerink Partnrs downgraded shares of Hologic from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 6th. Leerink Partners cut Hologic from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $80.00 to $75.00 in a report on Thursday, February 6th. Finally, Evercore ISI dropped their price target on Hologic from $76.00 to $73.00 and set an "in-line" rating for the company in a research note on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $84.62.

Hologic Trading Up 0.3 %

Shares of NASDAQ HOLX traded up $0.16 during midday trading on Tuesday, hitting $61.98. The company's stock had a trading volume of 3,766,525 shares, compared to its average volume of 1,712,542. Hologic, Inc. has a 12-month low of $59.55 and a 12-month high of $84.67. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The firm has a market cap of $13.91 billion, a P/E ratio of 19.55, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The business's 50 day moving average is $66.94 and its two-hundred day moving average is $74.51.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, equities research analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.